Want to see HK:2348 full AI Analyst Report?
Dawnrays Pharmaceutical Holdings Ltd. (2348) Ratios
Dawnrays Pharmaceutical Holdings Ltd. Ratios
HK:2348's free cash flow for Q2 2026 was $158.19M. For the 2026 fiscal year, HK:2348's free cash flow was decreased by $-50.30M and operating cash flow was $208.48M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.64 | 3.97 | 2.57 | 1.87 | 2.17 |
| Quick Ratio | 4.21 | 3.42 | 2.26 | 1.61 | 1.88 |
| Cash Ratio | 2.36 | 2.09 | 1.35 | 0.87 | 0.83 |
| Solvency Ratio | 0.54 | 0.94 | 0.54 | 0.42 | 0.44 |
| Operating Cash Flow Ratio | 0.72 | 0.40 | 0.51 | 0.47 | 0.56 |
| Short-Term Operating Cash Flow Coverage | 4.59 | 7.37 | 2.82 | 67.50 | 18.71 |
| Net Current Asset Value | $ 1.67B | $ 1.52B | $ 956.77M | $ 721.22M | $ 569.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.03 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.04 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.04 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.18 | 1.21 | 1.27 | 1.39 | 1.40 |
| Debt Service Coverage Ratio | 3.96 | 6.16 | 3.37 | 62.11 | 16.10 |
| Interest Coverage Ratio | 463.00 | 101.97 | 280.50 | 1138.57 | 594.01 |
| Debt to Market Cap | 0.05 | 0.02 | 0.08 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.05 | 0.03 | 0.08 | 0.01 | 0.02 |
| Net Debt to EBITDA | -3.13 | -4.01 | -1.57 | -1.59 | -1.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 45.29% | 54.48% | 55.73% | 60.01% | 57.96% |
| EBIT Margin | 18.48% | 19.06% | 36.06% | 34.34% | 32.68% |
| EBITDA Margin | 28.24% | 26.45% | 43.34% | 39.54% | 37.24% |
| Operating Profit Margin | 18.66% | 34.70% | 24.10% | 33.06% | 32.68% |
| Pretax Profit Margin | 20.28% | 60.07% | 35.97% | 34.31% | 37.71% |
| Net Profit Margin | 17.38% | 53.28% | 28.32% | 28.02% | 30.74% |
| Continuous Operations Profit Margin | 17.15% | 53.08% | 28.03% | 27.85% | 30.40% |
| Net Income Per EBT | 85.72% | 88.69% | 78.73% | 81.67% | 81.53% |
| EBT Per EBIT | 108.69% | 173.13% | 149.25% | 103.79% | 115.38% |
| Return on Assets (ROA) | 5.33% | 14.09% | 9.00% | 9.75% | 10.73% |
| Return on Equity (ROE) | 6.32% | 16.99% | 11.42% | 13.55% | 15.04% |
| Return on Capital Employed (ROCE) | 6.53% | 10.65% | 9.39% | 15.41% | 14.41% |
| Return on Invested Capital (ROIC) | 5.40% | 9.33% | 7.03% | 13.73% | 12.76% |
| Return on Tangible Assets | 6.12% | 16.29% | 10.12% | 10.78% | 11.94% |
| Earnings Yield | 12.98% | 32.74% | 22.59% | 20.35% | 17.59% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.64 | 2.08 | 3.58 | 3.17 | 3.36 |
| Payables Turnover | 3.87 | 2.18 | 3.14 | 2.28 | 3.42 |
| Inventory Turnover | 3.12 | 1.57 | 2.41 | 2.11 | 2.41 |
| Fixed Asset Turnover | 1.05 | 0.86 | 0.94 | 0.98 | 1.02 |
| Asset Turnover | 0.31 | 0.26 | 0.32 | 0.35 | 0.35 |
| Working Capital Turnover Ratio | 0.71 | 0.79 | 1.24 | 1.57 | 1.24 |
| Cash Conversion Cycle | 101.27 | 241.19 | 137.15 | 127.71 | 153.54 |
| Days of Sales Outstanding | 78.68 | 175.64 | 102.10 | 115.08 | 108.63 |
| Days of Inventory Outstanding | 116.81 | 233.09 | 151.20 | 172.67 | 151.63 |
| Days of Payables Outstanding | 94.22 | 167.54 | 116.14 | 160.05 | 106.72 |
| Operating Cycle | 195.50 | 408.73 | 253.29 | 287.76 | 260.27 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.24 | 0.15 | 0.23 | 0.29 | 0.26 |
| Free Cash Flow Per Share | 0.16 | 0.03 | 0.08 | 0.15 | 0.05 |
| Dividend Paid and CapEx Coverage Ratio | 1.41 | 0.77 | 1.03 | 1.43 | 0.86 |
| Capital Expenditure Coverage Ratio | 2.98 | 1.25 | 1.60 | 2.12 | 1.26 |
| Operating Cash Flow Coverage Ratio | 4.59 | 6.34 | 2.81 | 51.62 | 16.72 |
| Operating Cash Flow to Sales Ratio | 0.29 | 0.21 | 0.29 | 0.34 | 0.34 |
| Free Cash Flow Yield | 14.32% | 2.58% | 8.76% | 13.06% | 3.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7.83 | 3.05 | 4.43 | 4.92 | 5.69 |
| Price-to-Sales (P/S) Ratio | 1.34 | 1.63 | 1.25 | 1.38 | 1.75 |
| Price-to-Book (P/B) Ratio | 0.49 | 0.52 | 0.51 | 0.67 | 0.86 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.98 | 38.71 | 11.42 | 7.65 | 25.44 |
| Price-to-Operating Cash Flow Ratio | 4.64 | 7.84 | 4.26 | 4.05 | 5.18 |
| Price-to-Earnings Growth (PEG) Ratio | -0.12 | 0.04 | -0.53 | 0.00 | 0.14 |
| Enterprise Value Multiple | 1.61 | 2.15 | 1.32 | 1.89 | 3.42 |
| Enterprise Value | 558.46M | 601.73M | 657.61M | 956.61M | 1.48B |
| EV to EBITDA | 1.61 | 2.15 | 1.32 | 1.89 | 3.42 |
| EV to Sales | 0.45 | 0.57 | 0.57 | 0.75 | 1.27 |
| EV to Free Cash Flow | 2.37 | 13.50 | 5.20 | 4.16 | 18.51 |
| EV to Operating Cash Flow | 1.57 | 2.73 | 1.94 | 2.20 | 3.77 |
| Tangible Book Value Per Share | 1.91 | 1.85 | 1.64 | 1.53 | 1.37 |
| Shareholders’ Equity Per Share | 2.25 | 2.21 | 1.90 | 1.76 | 1.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.12 | 0.22 | 0.19 | 0.19 |
| Revenue Per Share | 0.82 | 0.70 | 0.77 | 0.85 | 0.78 |
| Net Income Per Share | 0.14 | 0.38 | 0.22 | 0.24 | 0.24 |
| Tax Burden | 0.86 | 0.89 | 0.79 | 0.82 | 0.82 |
| Interest Burden | 1.10 | 3.15 | 1.00 | 1.00 | 1.15 |
| Research & Development to Revenue | 0.07 | 0.07 | 0.08 | 0.06 | 0.06 |
| SG&A to Revenue | 0.20 | 0.24 | 0.10 | 0.10 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Income Quality | 1.42 | 0.35 | 0.82 | 1.21 | 1.10 |
Currency in CNY
